Our findings are consistent with a population-based cohort study on the UK Health Improvement Network (THIN) database, which detected no difference in the relative hazard of muscle toxicity, renal dysfunction or hepatic dysfunction in patients prescribed a statin CYP3A4 substrate versus a statin non-CYP3A4 substrate in co-medication with another CYP3A4 inhibitor [26]. This evidence concerns the gene CYP3A4 and Abnormal renal physiology.